SignalCorporate
GRAIL anticipates early Q1 2027 FDA decision while updating 2026 Galleri revenue growth to 17%-21%
GRAIL expects early Q1 2027 FDA decision and updates 2026 Galleri revenue growth to 17%-21%.
Context
What happened: GRAIL said its FDA Advisory Committee vote was favorable and it expects a final FDA decision by early Q1 2027. The company also updated its 2026 Galleri revenue growth outlook.
Key numbers: 2026 Galleri revenue growth guidance of 17% to 21%. Final FDA decision expected by early Q1 2027.
Why it matters: The advisory vote and expected decision timing set the regulatory path for Galleri, while the updated revenue growth range resets expectations for 2026.
What changed
GRAIL said its FDA Advisory Committee vote was favorable and it expects a final FDA decision by early Q1 2027. The company also updated its 2026 Galleri revenue growth outlook.
Why it matters
The advisory vote and expected decision timing set the regulatory path for Galleri, while the updated revenue growth range resets expectations for 2026.